{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3.0","upperLimit":"5.6","value":"4.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"105"}],"units":"Participants"}],"description":"Event-free survival is defined as the interval from the date of the first dose to the date of documented relapse, progression, or death due to any cause, whichever occurred first. Participants without an EFS event were censored at the date of the last adequate response assessment.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received enasidenib 100 mg QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.","id":"OG000","title":"Phase 2: Enasidenib 100 mg QD"}],"paramType":"MEDIAN","populationDescription":"All participants In Phase 2 with R/R AML who received at least 1 dose of study treatment.","reportingStatus":"POSTED","timeFrame":"From first dose of study treatment to the data cut-off date of 01 September 2017; median time on follow-up in Phase 2 was 5.8 months (range 0.4 to 22.5 months).","title":"Phase 2 Dose Expansion: Kaplan-Meier Estimate of Event Free Survival","type":"SECONDARY","unitOfMeasure":"months"}